Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone610-640-4202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$52.78 million
Profitability
Miscellaneous
Employees191
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
Neuronetics (NASDAQ:STIM) Frequently Asked Questions
What is Neuronetics' stock symbol?
Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How were Neuronetics' earnings last quarter?
Neuronetics Inc (NASDAQ:STIM) posted its earnings results on Tuesday, August, 6th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.43) by $0.04. The company earned $16.57 million during the quarter, compared to analysts' expectations of $15.80 million. Neuronetics had a negative net margin of 43.85% and a negative return on equity of 37.75%. View Neuronetics' Earnings History.
When is Neuronetics' next earnings date?
What guidance has Neuronetics issued on next quarter's earnings?
Neuronetics updated its third quarter 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $15.8-16.4 million, compared to the consensus revenue estimate of $16.24 million.
What price target have analysts set for STIM?
2 equities research analysts have issued 12 month price targets for Neuronetics' stock. Their predictions range from $25.00 to $28.00. On average, they anticipate Neuronetics' stock price to reach $26.50 in the next twelve months. This suggests a possible upside of 140.9% from the stock's current price. View Analyst Price Targets for Neuronetics.
What is the consensus analysts' recommendation for Neuronetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.
What are Wall Street analysts saying about Neuronetics stock?
Here are some recent quotes from research analysts about Neuronetics stock:
- 1. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (5/8/2019)
- 2. BTIG Research analysts commented, "$25 PT Neuronetics reported 4Q18 results with both capital sales and treatment revenue surpassing our forecast. Ending BDM count was in-line with expectations, implying rep productivity is ahead of planned (mgmt confirmed the same). Looking ahead to FY19, top-line guidance brackets current Street estimates. Mgmt is assuming more rep hires than the Street, driving up the operating expense outlook. On underlying assumptions, mgmt appears to be basing forecasts on historical productivity metrics instead of more recent encouraging trends likely creating upside. Additionally, the company does not appear to be aggressively signaling gross margin expansion though we still feel a greater mix of higher-margin consumable sales should push this metric higher." (3/6/2019)
Has Neuronetics been receiving favorable news coverage?
News headlines about STIM stock have trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neuronetics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Neuronetics.
Who are some of Neuronetics' key competitors?
Some companies that are related to Neuronetics include Anika Therapeutics (ANIK), Cerus (CERS), LeMaitre Vascular (LMAT), AngioDynamics (ANGO), SurModics (SRDX), Antares Pharma (ATRS), MiMedx Group (MDXG), Orthopediatrics (KIDS), Intersect ENT (XENT), SI-Bone (SIBN), OraSure Technologies (OSUR), Utah Medical Products (UTMD), Alphatec (ATEC), GenMark Diagnostics (GNMK) and Pulse Biosciences (PLSE).
What other stocks do shareholders of Neuronetics own?
Who are Neuronetics' key executives?
Neuronetics' management team includes the folowing people:
- Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)
- Mr. Peter L. Donato, CFO, VP & Corp. Sec. (Age 49)
- Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)
- Ms. Cassie Hallberg, VP of Marketing
- Mr. Daniel Guthrie, Chief Commercial Officer & VP (Age 42)
When did Neuronetics IPO?
(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
Who are Neuronetics' major shareholders?
Neuronetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.29%), Novo Holdings A S (3.15%), Vanguard Group Inc. (2.65%), Wells Fargo & Company MN (2.15%), Cortina Asset Management LLC (2.08%) and Wasatch Advisors Inc. (2.08%). Company insiders that own Neuronetics stock include Christopher Thatcher, Daniel Guthrie, Peter Donato and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.
Which major investors are selling Neuronetics stock?
STIM stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Granite Investment Partners LLC, JPMorgan Chase & Co., Citadel Advisors LLC and Alambic Investment Management L.P.. Company insiders that have sold Neuronetics company stock in the last year include Christopher Thatcher, Daniel Guthrie and Peter Donato. View Insider Buying and Selling for Neuronetics.
Which major investors are buying Neuronetics stock?
STIM stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Cortina Asset Management LLC, Wasatch Advisors Inc., Wells Fargo & Company MN, Vanguard Group Inc., Novo Holdings A S, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.
How do I buy shares of Neuronetics?
Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Neuronetics' stock price today?
One share of STIM stock can currently be purchased for approximately $11.00.
How big of a company is Neuronetics?
Neuronetics has a market capitalization of $203.39 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. Neuronetics employs 191 workers across the globe.View Additional Information About Neuronetics.
What is Neuronetics' official website?
How can I contact Neuronetics?
Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]
MarketBeat Community Rating for Neuronetics (NASDAQ STIM)
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
